Comparative evaluation of microfluidic-synthesized nano-niosomes versus liposomal and micro-niosomal deferoxamine in murine iron overload models

Ali Bazi, Somayyeh Karami-Mohajeri, Hajar Mardani Valandani, Elham Jafari, Fatemeh Oroojalian, Abbas Pardakhty, Roohollah Mirzaee Khalilabadi

Abstract


Background and purpose: Microfluidic technology provides enhanced standardization for formulating nanoencapsulated drugs compared to traditional bulk methodologies. Here, microfluidic nano-niosomal deferoxamine (Nn-DFO) was compared to micro-niosomal (Mn-DFO) and liposomal (L-DFO) formulations synthesized by conventional thin-film hydration.

Experimental approach: The formulations were subjected to physicochemical analyses. In vivo functional efficacy and safety were analyzed in mouse models of iron overload. Urinary and fecal iron excretion were also assessed.

Findings/Results: Mean particle sizes were 180.89±74.34 nm for L-DFO, 87.06±2.67 nm for Nn-DFO, and               7.41 ± 0.19 µm for Mn-DFO. Encapsulation efficiencies of L-DFO, Nn-DFO, and Mn-DFO formulations were 64.54%, 57.1%, and 70.72%, respectively. The 4-h drug release rates for L-DFO, Nn-DFO, and Mn-DFO formulations were 20.95%, 31.34%, and 26.30%, respectively, compared to 59.46% release from free DFO (F-DFO) within 4 h. Animals treated with F-DFO, L-DFO, Nn-DFO, and Mn-DFO showed significant reductions in the iron content of the liver (45.03%, 49.36%, 41.63%, and 23.52%, respectively). Urinary iron excretion on day 1st and fecal iron excretion on day 3rd after drug administration were the highest in the groups treated with F-DFO and Nn-DFO compared to other groups. Fecal iron excretion on day 7th was the highest in mice receiving Nn-DFO compared to different formulations.

Conclusion and implications: Nn-DFO synthesized by the microfluidic approach showed iron chelation efficacy and immediate iron excretion profile comparable to F-DFO, while being superior to Mn-DFO and L-DFO regarding delayed iron excretion.

 


Keywords


Drug carriers; Drug delivery systems; Iron chelating agents; Microfluidics.

Full Text:

PDF

References


Yang A, Du L, Gao W, Liu B, Chen Y, Wang Y, et al. Associations of cortical iron accumulation with cognition and cerebral atrophy in Alzheimer’s disease. Quant Imaging Med Surg. 2022;12(9):4570-5486.DOI: 10.21037/qims-22-7.

Zhou CH, Zhu YC. Imaging of cerebral iron as an emerging marker for brain aging, neurodegeneration, and cerebrovascular diseases. Brain Sci. 2025;15(9):944,1-19.DOI: 10.3390/brainsci15090944.

Mancardi D, Mezzanotte M, Arrigo E, Barinotti A, Roetto A. Iron overload, oxidative stress, and ferroptosis in the failing heart and liver. Antioxidants. 2021;10(12):1864,1-18.DOI: 10.3390/antiox10121864.

Tyagi P, Kumar A, Gupta D, Singh H. Decorporation of iron metal using dialdehyde cellulose-deferoxamine microcarrier. AAPS Pharm Sci Tech. 2017;18(1):156-165.DOI: 10.1208/s12249-016-0499-x.

Kontoghiorghes GJ. Iron load toxicity in medicine: from molecular and cellular aspects to clinical implications. Int J Mol Sci. 2023;24(16):12928.DOI: 10.3390/ijms241612928.

Entezari S, Haghi SM, Norouzkhani N, Sahebnazar B, Vosoughian F, Akbarzadeh D, et al. Iron chelators in treatment of iron overload. J Toxicol. 2022;2022(4):1-18.DOI: 10.1155/2022/4911205.

Hwang Y-F, Brown EB. Evaluation of deferoxamine in iron overload. Arch Intern Med. 1964;114(6):741-753.DOI: 10.1001/archinte.1964.03860120053003.

Huang V, Luini C, El-Ali A, Kessabi S. Iron chelation therapy: a review of the literature on the issues and importance of adherence to treatment in iron overload. Blood. 2015;126(23):4748.DOI: 10.1182/blood.V126.23.4748.4748.

Hamilton JL, Kizhakkedathu JN. Polymeric nanocarriers for the treatment of systemic iron overload. Mol and Cell Ther. 2015;3(1):3,1-15.DOI: 10.1186/s40591-015-0039-1.

Mukherjee S, Reddy A, Dutta N, Vaiphei KK, Vivek, Kumar A, et al. Exploring the potential of repurposed deferoxamine: bridging challenges and novel formulation opportunities. Nanomedicine. 2025: 20(16):2117-2141.DOI: 10.1080/17435889.2025.2534318.

Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci. 2018;13(4):288-303.DOI: 10.4103/1735-5362.235156.

Marzban A, Akbarzadeh A, Ardestani MS, Ardestani F, Akbari M. Synthesis of nano‐niosomal deferoxamine and evaluation of its functional characteristics to apply as an iron‐chelating agent. Can J Chem Eng. 2018;96(1):107-112.DOI: 10.1002/cjce.23048.

Rossi NA, Mustafa I, Jackson JK, Burt HM, Horte SA, Scott MD, et al. In vitro chelating, cytotoxicity, and blood compatibility of degradable poly (ethylene glycol)-based macromolecular iron chelators. Biomaterials. 2009;30(4):638-648.DOI: 10.1016/j.biomaterials.2008.09.057.

Salimi A, Zadeh BSM, Kazemi M. Preparation and optimization of polymeric micelles as an oral drug delivery system for deferoxamine mesylate: in vitro and ex vivo studies. Res Pharm Sci. 2019;14(4):293-307.DOI: 10.4103/1735-5362.263554.

Bartelds R, Nematollahi MH, Pols T, Stuart MC, Pardakhty A, Asadikaram G, et al. Niosomes, an alternative for liposomal delivery. PLoS One. 2018;13(4):e0194179,1-18.DOI: 10.1371/journal.pone.0194179.

Amoabediny G, Haghiralsadat F, Naderinezhad S, Helder MN, Akhoundi Kharanaghi E, Mohammadnejad Arough J, et al. Overview of preparation methods of polymeric and lipid-based (niosome, solid lipid, liposome) nanoparticles:a comprehensive review. Int J Polym Mater Polym Biomater. 2018;67(3):383-400. DOI: 10.1080/00914037.2017.1332623.

Thabet Y, Elsabahy M, Eissa NG. Methods for preparation of niosomes:a focus on thin-film hydration method. Methods. 2022;199:9-15.DOI: 10.1016/j.ymeth.2021.05.004.

Ag Seleci D, Maurer V, Stahl F, Scheper T, Garnweitner G. Rapid microfluidic preparation of niosomes for targeted drug delivery. Int J Mol Sci. 2019;20(19):4696,1-12.DOI: 10.3390/ijms20194696.

Aljabali AA, Tambuwala MM, Obeid MA. Microfluidic manufacturing of niosomes. Microfluidics in Pharmaceutical Sciences. 2024:77-108.DOI: 10.1007/978-3-031-60717-2_4.

Obeid MA, Khadra I, Aljabali AA, Amawi H, Ferro VA. Characterisation of niosome nanoparticles prepared by microfluidic mixing for drug delivery. Int J Pharm X. 2022;4:100137,1-7.DOI: 10.1016/j.ijpx.2022.100137.

Shokoohinia P, Hajialyani M, Sadrjavadi K, Akbari M, Rahimi M, Khaledian S, et al. Microfluidic-assisted preparation of PLGA nanoparticles for drug delivery purposes: experimental study and computational fluid dynamic simulation. Res Pharm Sci. 2019;14(5):459-470.DOI: 10.4103/1735-5362.268207.

Alam MK. Nanocarrier‐based drug delivery systems using microfluidic‐assisted techniques. Adv NanoBiomed Res. 2023;3(11):2300041,1-38.DOI: 10.1002/anbr.202300041.

Liu Z, Lin TM, Purro M, Xiong MP. Enzymatically biodegradable polyrotaxane–deferoxamine conjugates for iron chelation. ACS Appl Mater Interfaces. 2016;8(39):25788-25797.DOI: 10.1021/acsami.6b09077.

Hamilton JL, Imran ul-haq M, Abbina S, Kalathottukaren MT, Lai BF, Hatef A, et al. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator. Biomaterials. 2016;102:58-71.DOI: 10.1016/j.biomaterials.2016.06.019.

Uddin AH, Khalid RS, Alaama M, Abdualkader AM, Kasmuri A, Abbas S. Comparative study of three digestion methods for elemental analysis in traditional medicine products using atomic absorption spectrometry. J Anal Sci Technol. 2016;7(1):6,1-7.DOI: 10.1186/s40543-016-0085-6.

Al Sabaa H, Mady FM, Hussein AK, Abdel-Wahab HM, Ragaie MH. Dapsone in topical niosomes for treatment of acne vulgaris. Afr J Pharm Pharmacol. 2018;12(18):221-230.DOI: 10.5897/AJPP2018.4925.

El-Say KM, Abd-Allah FI, Lila AE, Hassan AE-SA, Kassem AEA. Diacerein niosomal gel for topical delivery: development, in vitro and in vivo assessment. J Liposome Res. 2016;26(1):57-68.DOI: 10.3109/08982104.2015.1029495.

Tran DT, Hayes ME, Noble CO, Dai Z, Working PK, Szoka FC. Twice monthly liposome encapsulated deferoxamine (LDFO) has a high molar efficiency in removing total body iron in an iron dextran-overloaded mouse model. Blood. 2016;128(22):2322-2225.DOI: 10.1182/blood.V128.22.2322.2322.

Ribeiro CM, Roque-Borda CA, Franzini MC, Manieri KF, Demarqui FM, Campos DL, et al. Liposome-siderophore conjugates loaded with moxifloxacin serve as a model for drug delivery against Mycobacterium tuberculosis. Int J Pharm. 2024;655:124050.DOI: 10.1016/j.ijpharm.2024.124050.

Guo S, Liu G, Frazer DM, Liu T, You L, Xu J, et al. Polymeric nanoparticles enhance the ability of deferoxamine to deplete hepatic and systemic iron. Nano Lett. 2018;18(9):5782-5790.DOI: 10.1021/acs.nanolett.8b02428.

Lang J, Zhao X, Wang X, Zhao Y, Li Y, Zhao R, et al. Targeted co-delivery of the iron chelator deferoxamine and a HIF1α inhibitor impairs pancreatic tumor growth. ACS nano. 2019;13(2):2176-2189.DOI: 10.1021/acsnano.8b08823.

Barani M, Sargazi S, Hajinezhad MR, Rahdar A, Sabir F, Pardakhty A, et al. Preparation of pH-responsive vesicular deferasirox: evidence from in silico, in vitro, and in vivo evaluations. ACS omega. 2021;6(37):24218-24232.DOI: 10.1021/acsomega.1c03816.

Jones G, Goswami SK, Kang H, Choi HS, Kim J. Combating iron overload: a case for deferoxamine-based nanochelators. Nanomedicine. 2020;15(13):1341-1356.DOI: 10.2217/nnm-2020-0038.

Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine. 2016;11(6):673-692.DOI: 10.2217/nnm.16.5.

Gong L, Wang Y, Liu J. Bioapplications of renal-clearable luminescent metal nanoparticles. Biomater Sci. 2017;5(8):1393-1406.DOI: 10.1039/C7BM00257B.

Zhu GH, Gray AB, Patra HK. Nanomedicine: controlling nanoparticle clearance for translational success. Trends Pharmacol Sci. 2022;43(9):709-711.DOI: 10.1016/j.tips.2022.05.001.

Clogston JD, Patri AK. Zeta potential measurement. Methods Mol Biol. 2011:697:63-70. DOI: 10.1007/978-1-60327-198-1_6.

Liang H, Zou F, Liu Q, Wang B, Fu L, Liang X, et al. Nanocrystal-loaded liposome for targeted delivery of poorly water-soluble antitumor drugs with high drug loading and stability towards efficient cancer therapy. Int J Pharm. 2021;599:120418,1-16.DOI: 10.1016/j.ijpharm.2021.120418.

Sułkowski W, Pentak D, Nowak K, Sułkowska A. The influence of temperature, cholesterol content and pH on liposome stability. J Mol Struct. 2005;744:737-747.DOI: 10.1016/j.molstruc.2004.11.075.

Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102,1-9.DOI: 10.1186/1556-276X-8-102.

Manosroi A, Wongtrakul P, Manosroi J, Sakai H, Sugawara F, Yuasa M, et al. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf B Biointerfaces. 2003;30(1-2):129-138.DOI: 10.1016/S0927-7765(03)00080-8.

Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185:22-36.DOI: 10.1016/j.jconrel.2014.04.015.

Toliyat T, Jorjani M, Khorasanirad Z. An extended-release formulation of desferrioxamine for subcutaneous administration. Drug Deliv. 2009;16(7):416-421. DOI10.1080/10717540903141768.

Nour S, Imani R, Mehrabani M, Solouk A, Iranpour M, Jalili-Firoozinezhad S, et al. Biomimetic hybrid scaffold containing niosomal deferoxamine promotes angiogenesis in full-thickness wounds. Mater Today Chem. 2023;27:101314.DOI: 10.1016/j.mtchem.2022.101314,1-19.

Agboluaje EO, Cui S, Grimsey NJ, Xiong MP. Bile acid–targeted hyaluronic acid nanoparticles for enhanced oral absorption of deferoxamine. AAPS J. 2024;26(3):46.DOI: 10.1208/s12248-024-00911-z.

Zhu F, Zhong J, Hu J, Yang P, Zhang J, Zhang M, et al. Carrier-free deferoxamine nanoparticles against iron overload in brain. CCS Chem. 2023;5(1):257-270.DOI: 10.31635/ccschem.022.202101696.

Abbina S, Abbasi U, Gill A, Wong K, Kalathottukaren MT, Kizhakkedathu JN. Design of safe nanotherapeutics for the excretion of excess systemic toxic iron. ACS Cent Sci. 2019;5(5):917-926.DOI: 10.1021/acscentsci.9b00284.

Imran ul-haq M, Hamilton JL, Lai BF, Shenoi RA, Horte S, Constantinescu I, et al. Design of long circulating nontoxic dendritic polymers for the removal of iron in vivo. ACS Nano. 2013;7(12):10704-10716.DOI: 10.1021/nn4035074.

Tian M, Chen X, Gu Z, Li H, Ma L, Qi X, et al. Synthesis and evaluation of oxidation-responsive alginate-deferoxamine conjugates with increased stability and low toxicity. Carbohydr Polym. 2016;144:522-530.DOI: 10.1016/j.carbpol.2016.03.014.

Nick H, Allegrini PR, Fozard L, Junker U, Rojkjaer L, Salie R, et al. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis. Exp Biol Med. 2009;234(5):492-503.DOI: 10.3181/0811-rm-337.

Wood JC, Otto-Duessel M, Gonzalez I, Aguilar MI, Shimada H, Nick H, et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res. 2006;148(5):272-280.DOI: 10.1016/j.trsl.2006.05.005.

Kang H, Han M, Xue J, Baek Y, Chang J, Hu S, et al. Renal clearable nanochelators for iron overload therapy. Nat Commun. 2019;10(1):5134,1-11. DOI: 10.1038/s41467-019-13143-z.

Wang Y, Liu Z, Lin TM, Chanana S, Xiong MP. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo. Int J Pharm. 2018;538(1-2):79-86.DOI: 10.1016/j.ijpharm.2018.01.004.

Guilmette R, Cerny E, Rahman YJLS. Pharmacokinetics of the iron chelator desferrioxamine as affected by liposome encapsulation: potential in treatment of chronic hemosiderosis. Life Sci. 1978;22(4):313-320.DOI: 10.1016/0024-3205(78)90138-8.

Lau EH, Cerny EA, Rahman YE. Liposome-encapsulated desferrioxamine in experimental iron overload. Br J Haematol. 1981;47(4):505-518.DOI: 10.1111/j.1365-2141.1981.tb02679.x.

Kesharwani R, Jaiswal P, Patel DK, Yadav PK. Lipid-based drug delivery system (LBDDS): an emerging paradigm to enhance oral bioavailability of poorly soluble drugs. Biomed Mater Devices. 2023;1(2):648-663.DOI: 10.1007/s44174-022-00041-0.

Zhao YQ, Li LJ, Zhou EF, Wang JY, Wang Y, Guo LM, et al. Lipid-based nanocarrier systems for drug delivery: advances and applications. Pharm Fronts. 2022;4(02):e43-e60.DOI: 10.1055/s-0042-1751036.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.